4//SEC Filing
Davis Robert M 4
Accession 0001127602-23-013808
CIK 0000310158other
Filed
Apr 27, 8:00 PM ET
Accepted
Apr 28, 5:15 PM ET
Size
9.4 KB
Accession
0001127602-23-013808
Insider Transaction Report
Form 4
Davis Robert M
DirectorChairman, CEO & President
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-04-28−143,329→ 0 totalExercise: $56.04From: 2019-05-04Exp: 2028-05-03→ Common Stock (143,329 underlying) - Exercise/Conversion
Common Stock
2023-04-28$56.04/sh+143,329$8,032,157→ 415,145.757 total - Sale
Common Stock
2023-04-28$114.93/sh−143,329$16,472,845→ 271,816.757 total
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.5200 to $115.3300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- [F2]Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.
- [F3]The option became exercisable in equal installments on 5/4/2019, 5/4/2020, and 5/4/2021.
Documents
Issuer
Merck & Co., Inc.
CIK 0000310158
Entity typeother
Related Parties
1- filerCIK 0001363076
Filing Metadata
- Form type
- 4
- Filed
- Apr 27, 8:00 PM ET
- Accepted
- Apr 28, 5:15 PM ET
- Size
- 9.4 KB